Washington, District of Columbia 20037


Purpose:

Evaluate the use of brief serial real time continuous monitoring (RT-CGM) as a behavior modification tool in obese patients with prediabetes and diabetes. After receiving RT-CGM, nutrition and exercise education, participants will be able to monitor their blood sugar in real time for 2 sessions . Education on how to interpret CGM in the setting of food choices and exercise coupled with nutrition and exercise information should lead to improved weight and other nutritional and exercise changes.


Criteria:

Inclusion Criteria: 1. Age 18-55 2. Prediabetes (A1c 6.0-6.4) or Diabetes (A1c 7.0-10) 3. BMI ≥ 30 kg/m2 4. Willing to wear pedometer during study period 5. Able to walk 2 city blocks at baseline without assistance (self-reported) 6. Reading level at least 6th grade in English 7. Expected to remain in local community for at least 4 months 8. Either is not treated with or has been on a stable treatment regimen of any of the following medications for a minimum of 3 months prior to Visit 1 (Screening/Enrollment): 1. Sulfonylureas 2. Biguanidine 3. Thyroid replacement therapy 4. Glp-1 agonists 5. Sodium-glucose co-transporters 6. Basal insulin 7. Thiazolidinediones 8. Hormone replacement therapy (female subjects) estrogen/progesterone products 9. Oral contraceptives/birth control (female subjects) 10. Antidepressant agents (SSRIs, Paxil, Prozac, Celexa, Zoloft, etc.) 9. Is able to read, understand, and sign the Informed Consent Form (ICF) and if applicable, an Authorization to Use and Disclose Protected Health Information form (consistent with Health Insurance Portability and Accountability Act of 1996 [HIPAA] legislation), communicate with the investigator, and understand and comply with protocol requirements. Exclusion Criteria: 1. Women who are pregnant, lactating, planning to become pregnant 2. Subjects who are taking amphetamines, anabolic, or weight-reducing agents 3. Contraindications to moderate exercise 4. Pre-prandial insulin 5. On any antipsychotic medication or history of schizophrenia or bipolar disorder 6. Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months 7. Active wounds or recent surgery within 3 months 8. Inflammatory disease, or chronic and current use of anti-inflammatory drugs or narcotics 9. Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study 10. Presence or history of severe congestive heart failure (New York Heart Association Class IV [CCNYHA 1994]) 11. Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant 12. Enrolled in another weight loss program 13. Already receiving continuous glucose monitoring (CGM)


NCT ID:

NCT03805412


Primary Contact:

Principal Investigator
Nicole Ehrhardt, MD
George Washington University

Nicole Ehrhardt, MD
Phone: 202-741-2443
Email: diabetesresearch@mfa.gwu.edu


Backup Contact:

Email: diabetesresearch@mfa.gwu.edu
Maria Zumer, PA-C, MPH
Phone: 202-741-2443


Location Contact:

Washington, District of Columbia 20037
United States

Nicole Ehrhardt, MD
Phone: 202-741-2443
Email: diabetesresearch@mfa.gwu.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.